Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence

This study has been completed.
Information provided by:
APOGEPHA Arzneimittel GmbH Identifier:
First received: January 16, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted
The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.

Condition Intervention Phase
Overactive Bladder
Urinary Incontinence
Drug: Mictonetten 5 mg, coated tablet
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial

Resource links provided by NLM:

Further study details as provided by APOGEPHA Arzneimittel GmbH:

Primary Outcome Measures:
  • voiding frequency [ Time Frame: before therapy and at end of therapy ]

Secondary Outcome Measures:
  • voided volume [ Time Frame: before and at end of treatment ]
  • incontinence episodes per day [ Time Frame: before and at end of therapy ]
  • safety parameters: acute urinary retention, post void residual urine, urinalysis, ECG, blood pressure, pulse rate [ Time Frame: before and at end of treatment ]

Enrollment: 303
Study Start Date: June 2004
Study Completion Date: December 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Mictonetten 5 mg, coated tablet
propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
Other Name: Mictonetten
Placebo Comparator: 2 Drug: placebo
placebo corresponding to body weight

Detailed Description:
This clinical trial showed superior efficacy of propiverine over placebo and convincing tolerability for the treatment of children suffering from OAB and urinary incontinence.

Ages Eligible for Study:   5 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • voiding frequency 8 or above per day
  • at least one incontinence episode per day
  • age between 5-10 years
  • body weight between 17 and 45 kg

Exclusion Criteria:

  • normal age expected bladder capacity
  • PVR more than 10 ml
  • dysfunctional voiding
  • neurogenic disorders
  • UTI, constipation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00603343

Sponsors and Collaborators
APOGEPHA Arzneimittel GmbH
Principal Investigator: Daniela Marschall-Kehrel, MD urologist
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: APOGEPHA, APOGEPHA Arzneimittel GmbH Identifier: NCT00603343     History of Changes
Other Study ID Numbers: EudraCT-Number 200400124330
Study First Received: January 16, 2008
Last Updated: January 16, 2008

Keywords provided by APOGEPHA Arzneimittel GmbH:
overactive bladder
urinary incontinence

Additional relevant MeSH terms:
Urinary Incontinence
Urinary Bladder, Overactive
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Urinary Bladder Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Urological Agents processed this record on May 25, 2017